A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT ID: NCT07204275
Last Updated: 2026-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2/PHASE3
176 participants
INTERVENTIONAL
2025-09-30
2028-12-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
NCT04629248
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142
The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy
NCT06614985
Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy
NCT03864250
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
NCT06470191
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 2b: Povetacicept
Participants will be randomized to receive one of the two doses of Povetacicept.
Povetacicept
Solution for Subcutaneous Injection.
Phase 3: Povetacicept
Participants will be randomized to receive one of the two doses of Povetacicept (dose selected based on Phase 2b).
Povetacicept
Solution for Subcutaneous Injection.
Phase 3: Calcineurin Inhibitor (CNI)
Participants will be randomized to receive the calcineurin inhibitor (CNI) Tacrolimus.
Tacrolimus
Capsules for Oral Administration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Povetacicept
Solution for Subcutaneous Injection.
Tacrolimus
Capsules for Oral Administration.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vertex Pharmaceuticals Incorporated
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Renal Associates
Montgomery, Alabama, United States
Southwest Kidney Institute, PLC (SKI) - Surprise
Surprise, Arizona, United States
Academic Medical Research Institute (AMRI)
Los Angeles, California, United States
Valiance Clinical Research - Internal Medicine
Tarzana, California, United States
Western Nephrology & Metabolic Bone Disease PC
Arvada, Colorado, United States
Bioresearch Partner
Miami, Florida, United States
CTR Oakwater, LLC
Orlando, Florida, United States
Clinical Site Partners, LLC - Orlando
Winter Park, Florida, United States
DaVita Clinical Research Columbus
Columbus, Georgia, United States
Georgia Nephrology
Lawrenceville, Georgia, United States
CARE Institute-Boise Kidney
Boise, Idaho, United States
NANI Research
Hinsdale, Illinois, United States
DaVita Clinical Research Edina
Edina, Minnesota, United States
Kidney Specialists of Southern Nevada
Las Vegas, Nevada, United States
Carolina Nephrology Greenville
Greenville, South Carolina, United States
Carolina Nephrology, PA
Spartanburg, South Carolina, United States
El Paso Kidney Specialists
El Paso, Texas, United States
Provecta Research Network
Houston, Texas, United States
DaVita Clinical Research Houston
Houston, Texas, United States
Davita Clinical Research San Antonio
San Antonio, Texas, United States
Utah Kidney Research
Salt Lake City, Utah, United States
Milwaukee Neprologists, SC
Wauwatosa, Wisconsin, United States
Peking University First Hospital
Beijing, , China
Dalian Municipal Central Hospital
Dalian, , China
Fuyang People's Hospital
Fuyang, , China
The People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, , China
The First Affiliated Hospital of Ningbo University
Ningbo, , China
Wuxi People's Hospital
Wuxi, , China
Yichang Central People Hospital
Yichang, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-521661-27-00
Identifier Type: OTHER
Identifier Source: secondary_id
VX24-AIS-D10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.